Pulmonary Function Testing (PFT) is a fundamental tool in the evaluation of respiratory diseases, offering valuable insights into the pathophysiology of the lungs. However, the interpretation of these tests can be complex and requires a comprehensive understanding. This article aims to provide a concise guide to decoding the essentials of PFT interpretation.
Spirometry is the most common PFT, measuring the volume and flow of air that can be inhaled and exhaled. Key parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio. These values aid in diagnosing obstructive and restrictive lung diseases.
These tests measure the lungs’ ability to transfer gases from inhaled air into the blood. The main parameter is Diffusion Capacity of the Lung for Carbon Monoxide (DLCO). Abnormal DLCO can indicate diseases such as emphysema, pulmonary fibrosis, or pulmonary hypertension.
Body plethysmography provides Total Lung Capacity (TLC), Residual Volume (RV), and Functional Residual Capacity (FRC). These values are crucial in diagnosing conditions like hyperinflation or air trapping, often seen in chronic obstructive pulmonary disease (COPD).
Interpreting PFT results involves comparing patient's values with predicted normal values, considering their age, gender, height, and ethnicity. A lower than normal FEV1/FVC ratio indicates obstructive disease, while a normal or high ratio with reduced volumes suggests restrictive disease. The severity is graded based on the degree of deviation from normal values.
PFTs are indispensable in diagnosing and managing respiratory diseases. Understanding the interpretation of these tests is crucial for healthcare professionals. While this guide offers a basic overview, a comprehensive understanding requires continuous learning and clinical experience.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation